Daxor to Participate in the Maxim Group 2021 Emerging Growth Virtual Conference
16 Março 2021 - 9:30AM
Daxor Corporation (NYSE: DXR), the global leader in blood volume
measurement technology, announces today that President and CEO
Michael Feldschuh will present at Maxim Group 2021 Emerging Growth
Virtual Conference to be held March 17-19, 2021, 9:00 AM - 5:00 PM
EST.
Mr. Feldschuh will highlight the many recent
accomplishments of the Company including accelerating revenue,
groundbreaking research and product development, contracts with the
US Department of Defense, grant funding through the NIH, and new
prospective medical trials for the use of Daxor’s BVA-100® blood
test in the management of critical care, COVID-19, and heart
failure with leading institutions.
Investors can view Mr. Feldschuh’s general
corporate presentation once they register for the conference, and
an archived replay of the presentation will be available via the
conference website. Investors can also request a one-on-one meeting
with Mr. Feldschuh following the conclusion of the conference.
Event: Maxim Group’s Inaugural Emerging Virtual
ConferenceDate: March 17th -19th, 9:00 AM - 5:00 PM ESTRegister
here.
Interested investors can contact Bret Shapiro at
COREIR either by calling 1-516-222-2560 or emailing
brets@coreir.com.
About Daxor CorporationDaxor
Corporation (NYSE: DXR) is the global leader in blood volume
measurement technology focused on blood volume testing innovation
(organized as an investment company with fully-owned innovative
medical instrumentation and biotechnology operations). We developed
and market the BVA-100® (Blood Volume Analyzer), the first
diagnostic blood test cleared by the FDA to provide safe, accurate,
objective quantification of blood volume status and composition
compared to patient-specific norms. The BVA technology enhances
hospital performance metrics in a broad range of surgical and
medical conditions, including heart failure and critical care, by
informing treatment strategies, resulting in significantly improved
multiple measures of patient outcomes. Daxor's mission is to
advance healthcare by enabling optimal fluid management with blood
volume analysis. Daxor’s vision is optimal blood volume for all.
For more information, please visit our website at Daxor.com.
Investor Relations Contact:Bret
ShapiroSr. Managing Partner, CORE
IR516-222-2560brets@coreir.com
Daxor (AMEX:DXR)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Daxor (AMEX:DXR)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
Notícias em tempo-real sobre Daxor Corporation da American Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de